Tag: HPV

Head and neck cancer data presented at ASCO 2023

Results from two promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT,…

Continue Reading Head and neck cancer data presented at ASCO 2023

Molecular Diagnostics Market Worth USD 18,542 million by

Chicago, June 02, 2023 (GLOBE NEWSWIRE) — The global market for molecular diagnostics is expected to reach USD 18,542 million by 2030 from USD 9,892 million in 2022, registering impressive expansion at a compound annual growth rate (CAGR) of 10.2%. Some of the major players are BD, bioMérieux SA, Bio-Rad…

Continue Reading Molecular Diagnostics Market Worth USD 18,542 million by

Plasmid DNA Manufacturing To See Impressive Growth In Years Ahead

By Sharvari Rale, Fairfield Market Research The quest for the most effective disease treatments has become more urgent than ever. The global chronic disease burden is swelling at alarming rates, pointing to growing severity of the situation for the global healthcare system, economy, and public health. Prevalence of chronic conditions…

Continue Reading Plasmid DNA Manufacturing To See Impressive Growth In Years Ahead

Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

SEOUL, South Korea–(BUSINESS WIRE)– Genexine (KQ 095700, CEO Neil Warma), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy…

Continue Reading Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

Point-of-care Molecular Diagnostics Market is rising to US$ 11.1 billion by 2033 is estimated at a CAGR of 9.7%

The Point-Of-Care Molecular Diagnostics Market is predicted to secure a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is estimated at a CAGR of 9.7% during the forecast period. Rising infectious and chronic diseases, such as cardiovascular, diabetes, and COVID-19, are increasing…

Continue Reading Point-of-care Molecular Diagnostics Market is rising to US$ 11.1 billion by 2033 is estimated at a CAGR of 9.7%

Respiratory eukaryotic virome expansion and bacteriophage deficiency characterize childhood asthma

Holgate, S. T. et al. Asthma. Nat. Rev. Disease Primers 1, 15025. doi.org/10.1038/nrdp.2015.25 (2015). Article  PubMed  Google Scholar  Juhn, Y. J. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease?. J. Allergy Clin. Immunol. 134, 247–257. doi.org/10.1016/j.jaci.2014.04.024 (2014). Article  PubMed …

Continue Reading Respiratory eukaryotic virome expansion and bacteriophage deficiency characterize childhood asthma

Screening and verification of key ubiquitination genes

Introduction Liver cancer is the third most common cause of cancer death globally with hepatocellular carcinoma (HCC) accounting for the majority of liver cancer.1,2 Early HCC (stage I/II) treatment mainly includes radical surgical resection, radiofrequency ablation and liver transplantation.3,4 However, there is a lack of typical clinical symptoms with early-stage…

Continue Reading Screening and verification of key ubiquitination genes

Ministry seeks uniform coverage of early cancer detection program

Currently, the health system in Indonesia is more focused on prevention than treatment. Jakarta (ANTARA) – The Health Ministry is making efforts to step up its program for the early detection of cancer by implementing promotive and preventive measures uniformly across Indonesian regions. “Each pillar of health transformation has around…

Continue Reading Ministry seeks uniform coverage of early cancer detection program

Identifying signatures of positive selection in human populations from North Africa

Henn, B. M. et al. Genomic ancestry of North Africans supports back-to-Africa migrations. PLOS Genet. 8, e1002397 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  Arauna, L. R. et al. Recent historical migrations have shaped the gene pool of Arabs and Berbers in North Africa. Mol. Biol. Evol. 34, 318–329…

Continue Reading Identifying signatures of positive selection in human populations from North Africa

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Molecular profiling reveals common changes in matched pairs of HNSCC primary tumor and metastasis-derived cell lines Identification of both genetic and functional differences between primary and metastatic variants of HNSCC would be enabled by in vitro models derived independently from these sites from the same patient. Unfortunately, HNSCC tumor cells…

Continue Reading Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Bartholin’s gland cyst caused by Sneathia amnii: a case report | BMC Infectious Diseases

S amnii is an important but underappreciated pathogen affecting women’s health because of its complex nutritional requirements, slow growth patterns, and requirement of anaerobic conditions. S amnii causes bacterial vaginosis and poor reproductive and perinatal outcomes. Sneathia species (spp.) have been identified as members of Community State Type IV (CST-IV)…

Continue Reading Bartholin’s gland cyst caused by Sneathia amnii: a case report | BMC Infectious Diseases

6 biotech companies in Norway you should know about

Best known for its folklore and tales of the Vikings, Norway’s landscape boasts postcard-like islands and the northern lights. In addition to ranking top as one of the happiest nations in the world, the country relies on sectors like oil and gas, hydropower and aquaculture to strengthen its economic growth….

Continue Reading 6 biotech companies in Norway you should know about

X4 Pharmaceuticals Announces Positive Phase 3 Results

~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher) in the mavorixafor group vs. placebo group >70% reduction in mean total days with infections (2 weeks on mavorixafor treatment vs. 7…

Continue Reading X4 Pharmaceuticals Announces Positive Phase 3 Results

Small Interfering RNA (SiRNA) Market is projected to reach USD

Small Interfering RNA (SiRNA) Market is projected to reach USD 964.17 Million by 2030 : Cognitive Market Research Market Overview: – Small interfering RNA (siRNA) is a class of double-stranded RNA operating within the RNA interference (RNAi) pathway. They exert their effects by RNA interference (RNAi) of their target mRNA….

Continue Reading Small Interfering RNA (SiRNA) Market is projected to reach USD

Senior Research Associate – Bioinformatics job with F. Hoffmann-La Roche AG

The PositionWho you are The Bioinformatics Senior Research Associate is responsible for designing and troubleshooting PCR-based assays for use with the GenMark Dx ePlex platform. The ideal candidate must be able to work in a collaborative research and IVD product development environment and demonstrate ability to analyze sequence data to…

Continue Reading Senior Research Associate – Bioinformatics job with F. Hoffmann-La Roche AG

Bioinformatics Scientist – Vaxart, Inc.

About Us: Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration. Vaxart has demonstrated that its proprietary tablet vaccine delivery platform is suitable…

Continue Reading Bioinformatics Scientist – Vaxart, Inc.

jitendra singh: Indian vaccine market to reach valuation of Rs 252 bn by 2025: Jitendra Singh

Highlighting the country’s strides in the pharma and biotechnology sector, Union Minister Jitendra Singh on Sunday said the Indian vaccine market is expected to reach a valuation of Rs 252 billion by 2025. Singh, who is leading a high-level official Indian delegation of the Ministry of Science and Technology on…

Continue Reading jitendra singh: Indian vaccine market to reach valuation of Rs 252 bn by 2025: Jitendra Singh

Solid-Phase Extraction and Enhanced Amplification-Free Detection of Pathogens Integrated by Dual-Functional CRISPR-Cas12a

Abstract Public healthcare demands effective and pragmatic diagnostic tools to address the escalating challenges in infection management in resource-limited areas. Recent advance in CRISPR-based biosensing promises the development of next-generation tools for disease diagnostics, including point-of-care (POC) testing for infectious diseases. Currently prevailing strategy of developing CRISPR assays exploits only…

Continue Reading Solid-Phase Extraction and Enhanced Amplification-Free Detection of Pathogens Integrated by Dual-Functional CRISPR-Cas12a

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases,…

Continue Reading INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Global partners announce The Big Catch-up vaccination effort

WHO, UNICEF, Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation, along with Immunization Agenda 2030 and many other global and national health partners, are joining forces to call for “The Big Catch-up,” a targeted global effort to boost vaccination among children following declines driven by the COVID-19…

Continue Reading Global partners announce The Big Catch-up vaccination effort

How Vaccine Platforms Can Prepare Us for Future Pandemics

This article was originally published in February 2021. It has since been updated by Willow Shah-Neville on April 19, 2023. The COVID-19 pandemic exposed the weaknesses in our defenses. Vaccine platforms will be powerful tools for reacting faster to future pandemics. Multiple COVID-19 vaccines became available across the world to…

Continue Reading How Vaccine Platforms Can Prepare Us for Future Pandemics

Mitochondrial DNA content as a biomarker for oral carcinogenesis: correlation with clinicopathologic parameters

Background: Mitochondrial genome (mtDNA) exhibits greater vulnerability to mutations and/or copy number variations than nuclear counterpart (nDNA) in both normal and cancer cells due to oxidative stress generated by inflammation, viral infections, physical, mechanical, and chemical load. The study was designed to evaluate the mtDNA content in oral potentially malignant…

Continue Reading Mitochondrial DNA content as a biomarker for oral carcinogenesis: correlation with clinicopathologic parameters

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM

X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of…

Continue Reading X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) – X4 Pharmaceuticals (NASDAQ:XFOR)

X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. XFOR, a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the…

Continue Reading X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) – X4 Pharmaceuticals (NASDAQ:XFOR)

Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines | Virology Journal

To KK-W, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, Tam AR, Chung TW-H, Chan JF-W, Zhang AJ-X, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021;10(1):507–35. Article  CAS  PubMed  PubMed Central  Google Scholar  Gao Q, Bao L, Mao H,…

Continue Reading Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines | Virology Journal

Merck stock ends Phase 3 Keytruda trials after missing main goals (NYSE:MRK)

koto_feja/iStock via Getty Images Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday that the companies would halt two late-stage combination trials for cancer therapy Keytruda in melanoma and colorectal cancer after the studies fell short of main goals. The trials known as LEAP-003 and LEAP-017 were designed to evaluate the…

Continue Reading Merck stock ends Phase 3 Keytruda trials after missing main goals (NYSE:MRK)

10 cancer vaccine companies that have changed the game

A kind of immunotherapy, cancer vaccines have been around since the link between human papillomavirus (HPV) and cancer was discovered in the 1980s. For the prevention of cancers – cervical, vaginal, vulvar and anal cancers – caused by the virus, vaccines were developed, and later approved by the Food and…

Continue Reading 10 cancer vaccine companies that have changed the game

5’P metadegradome coverage for vaginal microbiome datasets

Coverage traks for  5´ monophosphorylated mRNA decay intermediates (5´P) in bacterial species from vaginal swabs. Bedgraph files provide information for the 5’P coverage for the forward and reverse strand. Datasets are provided for 8 samples (r1 to r8). Funding Swedish Foundation’s Starting Grant (Ragnar Söderberg Foundation) Wallenberg Academy Fellowship (KAW…

Continue Reading 5’P metadegradome coverage for vaginal microbiome datasets

Microfluidic space coding for multiple nucleic acid detection through CRISPR-Cas12a and RPA

Research background Rapid, cheap and multiple detection of polynucleic acid is of great significance to human health, but it is still a huge challenge. Here, this paper proposes a nucleic acid detection platform named MiCaR, which combines microfluidic equipment with CRISPR-Cas12a and recombinase polymerase amplification (RPA). With only one fluorescent…

Continue Reading Microfluidic space coding for multiple nucleic acid detection through CRISPR-Cas12a and RPA

Cancer vaccine research may have reached ‘tipping point’

March 22, 2023 10 min read Source/Disclosures Published by: Disclosures: Disis reports being a stockholder/founder of EpiThany; grants from Aston Sci. and Bavarian Nordic during the conduct of the breast cancer vaccine study; serving as editor of JAMA Oncology outside the submitted work; and royalties for a…

Continue Reading Cancer vaccine research may have reached ‘tipping point’

National Vaccination Day 2023, Theme, History and More

National Vaccination Day 2023 National Vaccine Day is celebrated on 16 March every year. The COVID-19 and subsequent development of vaccines have made information on vaccines especially relevant for candidates aspiring for various competitive examinations. The idea behind the celebration of National Vaccine Day is to spread awareness and highlight…

Continue Reading National Vaccination Day 2023, Theme, History and More

Molecular Biologist Thais Da Rocha Boeira Builds Bridges To USA Public Health Research And Development

– Advertisement – The Covid pandemic has thrust public health concerns into the limelight, receiving constant media coverage and gaining widespread cultural recognition. To address this heightened interest, the World Health Organization and its affiliated NGOs are launching initiatives, and private health firms are increasing their business ventures in this…

Continue Reading Molecular Biologist Thais Da Rocha Boeira Builds Bridges To USA Public Health Research And Development

Droplet Digital Quantification of Nucleic Acids with Cas13a – HKUST SPD

Bibliographic Details Author Liu, Xin Cui, Johnson Q. Yao, Shuhuai Issue Date 2021 Source MicroTAS 2021 – 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences, 2021, p. 89-90 Abstract The isothermal amplification coupled with CRISPR detection has attracted tremendous interest for the sensitive, specific, and qualitative detection…

Continue Reading Droplet Digital Quantification of Nucleic Acids with Cas13a – HKUST SPD

Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test

NEW YORK – Personalis said Tuesday that it is continuing a collaboration with AstraZeneca to explore the cancer sequencing firm’s Next Personal molecular residual disease (MRD) test in clinical research and drug development.  The two companies are evaluating the sensitivity and specificity of whole-genome-informed circulating tumor DNA testing that supports…

Continue Reading Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test

What are ‘cancer vaccines,’ and what similarities do they share with COVID vaccines?

Credit: Shutterstock Barely a month goes by without headlines announcing yet another advancement in cancer vaccines. Just last month, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation to Moderna and Merck’s skin cancer vaccine. This allows expedited development and review of drugs intended to treat serious…

Continue Reading What are ‘cancer vaccines,’ and what similarities do they share with COVID vaccines?

What are these ‘cancer vaccines’ I’m hearing about? And what similarities do they share with COVID vaccines?

Barely a month goes by without headlines announcing yet another advancement in cancer vaccines. Just last month, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation to Moderna and Merck’s skin cancer vaccine. This allows expedited development and review of drugs intended to treat serious conditions. We…

Continue Reading What are these ‘cancer vaccines’ I’m hearing about? And what similarities do they share with COVID vaccines?

Crosstalk between cGAS-STING pathway and autophagy in cancer immunity

1 Introduction Cancer is one of the world’s most serious threats to human health, with high morbidity and mortality rates, and according to the latest global data, 9.96 million patients will die from cancer in 2020 (1). Cancer is a genetic abnormal disease triggered by a long-term combination of multiple…

Continue Reading Crosstalk between cGAS-STING pathway and autophagy in cancer immunity

Discordance of p16 and HPV DNA/RNA Status: Prognostic Implication in Squamous Cell Oropharyngeal Carcinoma

By Matthew StengerPosted: 2/23/2023 10:09:00 AM Last Updated: 2/23/2023 12:56:40 PM In a study reported in The Lancet Oncology, Hisham Mehanna, FRCS, and colleagues found that concordance and discordance of p16 immunohistochemistry and human papillomavirus (HPV) DNA/RNA testing were associated with different outcomes among patients with squamous cell oropharyngeal carcinoma….

Continue Reading Discordance of p16 and HPV DNA/RNA Status: Prognostic Implication in Squamous Cell Oropharyngeal Carcinoma

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be

Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics…

Continue Reading Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be

Positive results for INOVIO recurrent respiratory papillomatosis trial

INOVIO has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults.  In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle,…

Continue Reading Positive results for INOVIO recurrent respiratory papillomatosis trial

Senior Research Associate – Bioinformatics at Roche in Carlsbad, CA 202301-102183

The Position Who you are The Bioinformatics Senior Research Associate is responsible for designing and troubleshooting PCR-based assays for use with the GenMark Dx ePlex® platform. The ideal candidate must be able to work in a collaborative research and IVD product development environment and demonstrate ability to analyze sequence data…

Continue Reading Senior Research Associate – Bioinformatics at Roche in Carlsbad, CA 202301-102183

Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial

Abstract Objectives To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma. Design Open-label, non-inferiority, multicentre, randomised, phase 3 trial. Setting Three Chinese hospitals between 20 November 2017 and 3 December 2018….

Continue Reading Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial

Leveraging Early Cancer Detection Tech

Cancer is fast turning into an ‘epidemic’ and is the second leading cause of death globally. As per the Globocan Report of 2020, the annual global burden of cancer in 2020 in the country had hit the 1.93 crore mark with an annual death of 1 crore. Let’s explore some…

Continue Reading Leveraging Early Cancer Detection Tech

Leveraging 16S rRNA data to uncover vaginal microbial signatures in women with cervical cancer

1 Introduction Cervical cancer (CC) remains the fourth most common cancer in women worldwide, with 604,127 new cases in 2020 and more than 341,831 deaths, accounting for nearly 8% of all female cancer-related deaths annually (Sung et al., 2021). This common infection-related neoplasm and its premalignant precursor are caused by high-risk…

Continue Reading Leveraging 16S rRNA data to uncover vaginal microbial signatures in women with cervical cancer

HPV DNA Test For Cervical Cancer Detection: With 99% Accuracy This Can Be A Game-Changer

The discovery of necessary cause of cervical cancer, human papilloma virus (HPV) has led to the development of molecular tests for HPV to identify women with cervical precancerous lesions. WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention. Of all the cancers that we have to…

Continue Reading HPV DNA Test For Cervical Cancer Detection: With 99% Accuracy This Can Be A Game-Changer

Master mitotic kinases regulate viral genome delivery during papillomavirus cell entry

Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729–740 (2006). Article  CAS  Google Scholar  Roe, T., Reynolds, T. C., Yu, G. & Brown, P. O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12, 2099–2108 (1993). Article  CAS  Google Scholar  Bieniasz, P. D., Weiss,…

Continue Reading Master mitotic kinases regulate viral genome delivery during papillomavirus cell entry

10 facts you should know about HPV

The human papillomavirus is the most common sexually transmitted infection (STI). HPV can be transmitted through skin-to-skin sexual contact so the transmission does not require sexual intercourse. Most sexually-active women contract the infection at some point in their lives with or without symptoms. However, in 9 out of 10 people…

Continue Reading 10 facts you should know about HPV

PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer

GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a…

Continue Reading PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer

Inovio Pharmaceuticals Stock Up By 28% In The Last 21 Sessions

(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose by a staggering 28.66% in 21 sessions from $1.64 at 2022-10-20, to $2.11 at 14:28 EST on Friday, after two sequential sessions in a row of losses. NASDAQ is falling 0.39% to $11,101.66, after two successive sessions in a row of…

Continue Reading Inovio Pharmaceuticals Stock Up By 28% In The Last 21 Sessions

Inovio Pharmaceuticals Stock Up Momentum With A 31% Rise In The Last 21 Sessions

(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose by a staggering 31.69% in 21 sessions from $1.83 at 2022-10-17, to $2.41 at 11:43 EST on Monday, following the last session’s downward trend. NASDAQ is falling 0.67% to $11,247.78, after two successive sessions in a row of gains. Inovio Pharmaceuticals’s…

Continue Reading Inovio Pharmaceuticals Stock Up Momentum With A 31% Rise In The Last 21 Sessions

Inovio Pharmaceuticals Stock Is 9% Up Today

(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose 9.15% to $1.79 at 16:14 EST on Friday, after four sequential sessions in a row of losses. NASDAQ is jumping 1.89% to $10,815.92, after two consecutive sessions in a row of losses. This seems, up until now, an all-around positive trend…

Continue Reading Inovio Pharmaceuticals Stock Is 9% Up Today

Inovio Pharmaceuticals Stock Was Up By 17.31% Today

(VIANEWS) – The NASDAQ ended the session with Inovio Pharmaceuticals (INO) rising 17.31% to $1.83 on Thursday while NASDAQ fell 0% to $0.00. Inovio Pharmaceuticals’s last close was $1.66, 78.64% under its 52-week high of $7.77. About Inovio Pharmaceuticals Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing,…

Continue Reading Inovio Pharmaceuticals Stock Was Up By 17.31% Today

Scientists develop more accurate predictive test for cervical cancer

The test can also pick up DNA markers for some other cancers, meaning it could in future be used as a predictive test for breast, womb, cervical and ovarian cancer. When tested for cervical cancer, it performed better than currently available methods for detecting those with advanced cell changes who…

Continue Reading Scientists develop more accurate predictive test for cervical cancer

More accurate test for cervical cancer ‘great news’, say campaigners

A more accurate test for cell changes that could lead to cervical cancer has been developed by scientists. The test can also pick up DNA markers for some other cancers, meaning it could in future be used as a predictive test for breast, womb, cervical and ovarian cancer. When tested…

Continue Reading More accurate test for cervical cancer ‘great news’, say campaigners

A novel causative functional mutation in GATA6 gene is responsible for familial dilated cardiomyopathy as supported by in silico functional analysis

Pérez-Serra, A. et al. Genetic basis of dilated cardiomyopathy. Int. J. Cardiol. 224, 461–472 (2016). PubMed  Article  Google Scholar  Petropoulou, E. et al. Digenic inheritance of mutations in the cardiac troponin (TNNT2) and cardiac beta myosin heavy chain (MYH7) as the cause of severe dilated cardiomyopathy. Eur. J. Med. Genet….

Continue Reading A novel causative functional mutation in GATA6 gene is responsible for familial dilated cardiomyopathy as supported by in silico functional analysis

Do preteens really need an HPV vaccine?

by Dr. Rebekah Fenton and Dr. Rebecca Perkins Gardasil vaccine and box. Image: Wikipedia Q: Why is it important for my 10-year-old to get the HPV vaccine? A: If you are the parent of a preteen who is between the ages of 9 and 12, it’s time to make sure…

Continue Reading Do preteens really need an HPV vaccine?

Using CRISPR/Cas to develop biosafety materials

The diagnosis and treatment of viral infections, especially those that cause large-scale outbreaks, is urgently needed, as the lack of these measures allows epidemics to progress. A new Biosafety and Health study discusses the use of the highly efficient clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) technology to…

Continue Reading Using CRISPR/Cas to develop biosafety materials

Optimization of cerebrospinal fluid microbial DNA metagenomic sequencing diagnostics

We implemented a metagenomic DNA sequencing methodology to unbiasedly detect microbial species in CSF samples from patients with CNS symptoms in which a pathogen or EBV had been detected (Additional 3: Table 1). Samples positively identified with pathogen-specific quantitative PCR (qPCR), 16S rRNA gene sequencing or bacterial/mycotic culture in CSF…

Continue Reading Optimization of cerebrospinal fluid microbial DNA metagenomic sequencing diagnostics

Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity

Significance Interferon (IFN)-mediated antiviral responses serve as the first line of the host innate immune defense against viral infection. Here we identify a previously uncharacterized protein designated phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein (PINLYP), which is essential for embryonic development and plays an important role in type I IFN…

Continue Reading Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity

CRISPR/Cas12a Powered DNA Framework-Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis

Nucleic acid analysis using ultrasensitive and simple methods is critically important for the early-stage diagnosis and treatment of diseases. The CRISPR/Cas proteins, guided by a single-stranded RNA have shown incredible capability for sequence-specific targeting and detection. Herein, in order to improve and expand the application of CRISPR/Cas technology to the…

Continue Reading CRISPR/Cas12a Powered DNA Framework-Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis

BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

NEWARK, Calif., Sept. 22, 2021 /PRNewswire/ — BioChain Institute, (“BioChain”), a leader in high quality processed bio-sample products, announced an expanded line of Next Generation Sequencing (NGS) characterized bio-samples encompassing a variety of cancer-related mutations available for preclinical drug development and as reference samples for CLIA labs.  “Scientists are looking for…

Continue Reading BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

Genotype distribution and prevalence of human papillomavirus

Introduction Cervical cancer (CC) is the second most deadly disease among women in the world and is the leading cause of death from cancer.1 In 2018, there were 570,000 new diseases and 311,000 deaths worldwide.2 Viral infections contribute to 15–20% of all cancers, and several viruses play an important role…

Continue Reading Genotype distribution and prevalence of human papillomavirus

National Health Commission responds on concerns about a third dose for people with high risk

Is it necessary to take the COVID-19 booster dose and are there any suggestions on traveling during the upcoming Mid-Autumn Festival and National Day holidays? These are some of the questions that are being raised currently. Here are the answers from the National Health Commission, which held a press conference…

Continue Reading National Health Commission responds on concerns about a third dose for people with high risk

Answers to commonly asked questions, KNEWS

As of July 2021, the coronavirus vaccine has been added to the National Vaccination Program for children and adolescents aged 12-17. Here are the most commonly asked questions and answers about the COVID-19 vaccine provided by the National Vaccination Committee. I hesitate to vaccinate my child because these vaccines…

Continue Reading Answers to commonly asked questions, KNEWS